FierceBiotechOriginal article
{"a":[{"_":"Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial","$":{"href":"/biotech/racing-takeda-innocare-reports-tyk2-inhibitor-win-phase-2-vitiligo-trial","hreflang":"en"}}]}
Phase 2positivesoficitinibPositive
AI Analysis
Summary
InnoCare Pharma's TYK2 inhibitor soficitinib met its primary endpoint in a phase 2 trial for nonsegmental vitiligo, advancing the program to phase 3. The positive result positions InnoCare to compete with Takeda in the TYK2 inhibitor space for vitiligo treatment.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Primary endpoint met in phase 2 trial of TYK2 inhibitor soficitinib in nonsegmental vitiligo
Importance:7/10
Sentiment:
0.75
TYK2 inhibitorvitiligophase 2 successdermatologyChina
Related Companies
Read the original article
Published by FierceBiotech on July 16, 2026 9:38 AM